Tocris Signs Exclusive Deal to Supply Gefitinib for Cancer Research
News Sep 05, 2008
For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib (also known as IressaTM and ZD1839) as an off-the shelf product for use in biological research.
In recent years pharmaceutical companies have developed a number of small molecule drugs that are clinically effective against certain types of cancer. Tyrosine kinase inhibitors (TKIs) such as Gefitinib are at the forefront of this new generation of targeted anticancer agents.
Gefitinib is an EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor), which targets and blocks the activity of the EGFR-TK, an enzyme that regulates intracellular signalling pathways implicated in cancer cell proliferation and survival. Growth factor signalling has been identified as a key driver of tumour growth and spread in a wide range of cancers. For clinical use, Gefitinib has been approved for the treatment of advanced Non Small Cell Lung Cancer (NSCLC) in 36 countries.
This molecule has been licensed to Tocris for use as a preclinical research compound only. Strict conditions have been imposed by AstraZeneca to ensure that it is not used in human studies.
Duncan Crawford, Tocris’ Chief Scientific Officer, said, “We know that there is a great deal of interest in Gefitinib from the global research community. By making fully licensed Gefitinib available through our catalogue, we hope to promote new and exciting research in the fundamental processes that drive cancer development. For Tocris this important new product perfectly compliments our comprehensive and expanding range of high purity compounds, which are in use worldwide to further biomedical research. We are delighted that our excellent relationship with AstraZeneca has allowed us to make this compound available to scientists working on the fundamental mechanisms of cancer cell biology”